Gabrielle Masson is a staff writer for Fierce Biotech, specializing in covering the latest developments and trends in the biotechnology industry. With her background in writing, her articles provide in-depth analysis and insights into the world of biotech, including topics such as mergers and acquisitions, IPOs, breakthrough therapies, and global biotech initiatives.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
International
Based on Gabrielle's coverage attributes, she seems to be focused primarily on press releases and data citations within the healthcare and pharmaceutical sector. Her articles revolve around biotechnology, pharmaceutical industry news, biotech funding, clinical trials, and drug development.
To effectively reach out to Gabrielle Masson with a pitch or information, consider providing well-researched data-backed insights related to developments in the field of biotechnology and pharmaceuticals. Additionally, experts who can offer commentary or analysis backed by credible sources may find her receptive.
As Gabrielle's geographic focus is not specified but given the nature of her topics covered which are often global in scope such as clinical trials and drug development it would be beneficial for pitches to reflect an international perspective when relevant.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Max Bayer, Gabrielle Masson
Welcome to this week's Chutes & Ladders, our ro
By: Gabrielle Masson
What does it feel like to be a woman CEO in biotech? An island, according to Gossamer Bio co-founder and former CEO Sheila Gujrathi, M.D.
By: Gabrielle Masson
After BioMarin’s new leadership conducted a “strategic R&D asset review,” three of its “most productive” assets are being
By: Gabrielle Masson, Max Bayer, Andrea Park
Welcome to this week's Chutes & Ladders,
By: Gabrielle Masson
Earlier this year, Metagenomi had the spotlight with a $93.7 million IPO.
Amgen is axing obesity candidate AMG 786 and going all in on later-stage asset MariTide.
By: Gabrielle Masson, Max Bayer
Welcome to this week's Chutes & Ladders, our roundup of hirings, firings and retirings throughout the industry.
By: Gabrielle Masson
Vertex Pharmaceuticals is ahead of schedule, filing a new drug application
By: Gabrielle Masson
A young boy with Duchenne muscular dystrophy (DMD) participating in Pfizer’s phase 2 gene therapy trial has died, the pharma shared in a May 7
By: Gabrielle Masson
In its ongoing mission to find the next Wegovy, Novo Nordisk has penned another partnership to seek out next-gen obesity treatments.
(833) 317-6278 
